Proteostasis Therapeutics is developing disease-modifying therapeutics for diseases of protein folding, trafficking and clearance. By combining the DRT™platform with state of the art medicinal chemistry tools, PTI generates highly selective drug candidates. The Company's proprietary Disease-Relevant Translation, DRT™ platform utilizes functionally pertinent phenotypic assays and disease relevant models to identify highly translatable therapies associated with the modulation of proteostasis pathways within the cell. PTI has multiple wholly owned programs in cystic fibrosis. In addition, PTI has a collaboration with Astellas Inc based on the Unfolded Protein Response (UPR) pathway where PTI is eligible to earn up to $1.2B in development milestones.